201 related articles for article (PubMed ID: 12610745)
1. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
Zdravkovic M; Olsen AK; Christiansen T; Schulz R; Taub ME; Thomsen MS; Rasmussen MH; Ilondo MM
Eur J Clin Pharmacol; 2003 Feb; 58(10):683-8. PubMed ID: 12610745
[TBL] [Abstract][Full Text] [Related]
2. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
4. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
7. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
12. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Andersen V; Pedersen N; Larsen NE; Sonne J; Larsen S
Br J Clin Pharmacol; 2002 Aug; 54(2):120-4. PubMed ID: 12207630
[TBL] [Abstract][Full Text] [Related]
13. Effects of metronidazole on midazolam metabolism in vitro and in vivo.
Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):555-9. PubMed ID: 11151744
[TBL] [Abstract][Full Text] [Related]
14. Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib.
Marcantonio EE; Ballard J; Gibson CR; Kassahun K; Palamanda J; Tang C; Evers R; Liu C; Zajic S; Mahon C; Mostoller K; Hreniuk D; Mehta A; Morris D; Wagner JA; Stoch SA
J Clin Pharmacol; 2014 Nov; 54(11):1280-9. PubMed ID: 24895078
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration.
Ren X; Mao X; Si L; Cao L; Xiong H; Qiu J; Schimmer AD; Li G
Eur J Pharm Biopharm; 2008 Sep; 70(1):279-88. PubMed ID: 18499414
[TBL] [Abstract][Full Text] [Related]
16. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
Svensson J; Monson JP; Vetter T; Hansen TK; Savine R; Kann P; Bex M; Reincke M; Hagen C; Beckers A; Ilondo MM; Zdravkovic M; Bengtsson BA; Korbonits M;
Clin Endocrinol (Oxf); 2003 May; 58(5):572-80. PubMed ID: 12699438
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers.
Zdravkovic M; Søgaard B; Ynddal L; Christiansen T; Agersø H; Thomsen MS; Falch JE; Ilondo MM
Growth Horm IGF Res; 2000 Aug; 10(4):193-8. PubMed ID: 11032702
[TBL] [Abstract][Full Text] [Related]
19. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
20. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
Stroh M; Dishy V; Radziszewski W; Hwang E; Lazarus-Shipitofsky N; Dittrich H; Johnson-Levonas AO; Lutz R; Wagner JA; Lai E
Am J Ther; 2010; 17(1):53-60. PubMed ID: 20027108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
